



PRESS RELEASE

**ADOCIA: additional contribution to the liquidity agreement**

**Lyon, France, September 17, 2015** - Adocia (Euronext Paris: FR0011184241 - ADOC) today announced an increase of EUR 200,000, effective as of September 17, 2015, to the means allocated to the liquidity agreement with Kepler Capital Markets S.A.

As a reminder, as of June 30, 2015, the following resources were allocated to the liquidity account:

- 2,257 shares of Adocia and
- 83,378.96 euros in cash.

This liquidity agreement, complying with the charter of ethics established by the French Financial Markets Association (A.M.A.F.I.) and approved by the French market authority (Autorité des marchés financiers) effective on March 21, 2011, aims to ensure the liquidity of ADOCIA company's shares on the regulated market Euronext Paris.

**About Adocia**

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia's proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. To learn more about Adocia, please visit us at [www.adocia.com](http://www.adocia.com).



**For more information please contact:**

<p><b>Adocia</b> Gérard Soula Chairman and CEO <a href="mailto:contactinvestisseurs@adocia.com">contactinvestisseurs@adocia.com</a> Tel.: +33 4 72 610 610</p>	<p><b>Adocia Press Relations</b> <b>ALIZE RP</b> Caroline Carmagnol and Florence Portejoie <a href="mailto:caroline@alizerp.com">caroline@alizerp.com</a> <a href="mailto:adocia@alizerp.com">adocia@alizerp.com</a> Tel.: + 33 1 44 54 36 61</p>
--	---